Announcement • Jan 02
CS Medica A/S Confirms the Delisting of the Company by Spotlight Stock Market The Board of Directors of CS MEDICA A/S ("CS MEDICA" or "the company") confirmed the delisting of the company by Spotlight Stock Market, effective January 9, 2025, is final. After an thorough evaluation of several company delisting's over the past year and a careful assessment of available options to protect shareholder interests, the Board of Directors has prioritized strengthening company growth and operations while exploring alternative trading solutions, leveraging proven strategies employed by other delisted companies, to safeguard shareholder and company value after the last trading day. Following the delisting, CS MEDICA will no longer be subject to the Spotlight Stock Market's disclosure obligations under the Market Abuse Regulation (MAR). Announcement • Dec 20
CS MEDICA Responds to Spotlight Stock Market's Delisting Notification On December 16, 2024, CS Medica A/S communicated to Spotlight Stock Market that the outstanding payments would be settled within the week. The payments were completed on December 19, 2024, just one day after the stated deadline of December 18. In addition, CS MEDICA had proposed paying the Spotlight fee a year in advance to demonstrate the company's improved financial stability. Despite these proactive efforts, Spotlight Stock Market released the delisting notification and has decided to proceed with delisting. We are deeply surprised and disappointed by this decision, particularly given the strong relationship and support CS MEDICA has enjoyed with Spotlight Stock Market over the years. The timing of this announcement on the day immediately following the payment deadline has added unnecessary complexity and challenges for our company and our shareholders. We still hope to solve the situation with Spotlight. CS MEDICA has always prioritized transparency, and we have openly communicated with our investors and stakeholders about the financial challenges we have faced in the recent year. This includes acknowledging the need for a cash injection to strengthen our financial position and our strategic goal of pursuing an IPO in Germany through our subsidiary. Overcoming these challenges has been a key focus for the company, and our founders have demonstrated their commitment by converting debt into shares, ensuring stability while fostering growth in a demanding market environment. This action underscores our dedication to mitigating risks and protecting shareholder interests. We want to assure our shareholders and stakeholders that this development does not impact our daily operations, strategic growth initiatives, or the intrinsic value of the company. CS MEDICA is actively exploring alternative listing options to ensure continuity and safeguard the interests of our shareholders. Updates on our progress and next steps will be communicated promptly through official press releases. Announcement • Dec 04
CS Medica A/S to Report Fiscal Year 2025 Final Results on Jan 10, 2026 CS Medica A/S announced that they will report fiscal year 2025 final results on Jan 10, 2026 
